Immuneering Corporation, located in Cambridge, Massachusetts, specializes in developing oncology and neuroscience product candidates for the treatment of cancer and solid tumors. Its lead product candidates include IMM-1-104 and IMM-6-415, and the company has five oncology programs in the discovery stage and two neuroscience programs. Founded in 2008, Immuneering Corporation was previously a subsidiary of Teva Pharmaceutical Industries Limited.